NCT01855867View on ClinicalTrials.gov

HIV Non-Occupational Post-Exposure Prophylaxis

PHASE4CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2016

Conditions

Human Immunodeficiency Virus

Interventions

DRUG

Single Dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)

Trial Locations (1)

02215

Fenway Community Health, Boston

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

Kenneth H. Mayer, MD

OTHER

NCT01855867 - HIV Non-Occupational Post-Exposure Prophylaxis | Biotech Hunter | Biotech Hunter